Abstract
Objective: We conducted a perspective study to investigate the association between mRNA expression quantities of ERCC1, BRCA1, RRM1 and RRM2 and response to chemotherapy and clinical outcome of advance Non-Small Cell Lung Cancer.(NSCLC). Methods: Two hundred eight patients who were diagnosed as advanced stage NSCLC were included in our study. A fluorescence-based and real-time detection method was used to determine the relative cDNA quantification for ERCC1, BRCA1, RRM1 and RRM2, and β-actin was used as the reference gene. Results: The median expression levels of ERCC1, BRCA1, RRM1 and RRM2 mRNA were 0.67±0.17, 0.095±0.012, 0.24±0.17 and 2.45±0.32, respectively. Our study found that the low ERCC1 (OR=1.82, 95% CI=1.01-3.20) and Low BRCA1 (OR=2.53, 95%CI=1.38-4.64) mRNA expression was more likely to response to chemotherapy when compared with high expression, respectively. Multivariate Cox regression analysis indicated that patients with low mRNA expression of ERCC1 and BRCA1 attained 0.43 (OR=0.43, 95%CI=0.27-0.89) and 0.37 (OR=0.37, 95%CI=0.22-0.66) fold risk of death from NSCLC. However, we found RMM1 and RRM2 mRNA expression could not influence the response to chemotherapy and clinical outcome of NSCLC. Conclusion: ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients.
Highlights
Lung cancer remains the most common cause of mortality from malignant disease in the world for several decades, and it has been the most common cancer in China.[1]
The expression of Excision repair cross complementing 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), RRM1 and RRM2 was classified into high and low expression according to median expression level
Our study found that the low ERCC1 and Low BRCA1 mRNA expression was more likely to be response to chemotherapy when compared with high expression, with the ORs of 1.82(1.01-3.20) and 2.53(1.384.64), respectively
Summary
Lung cancer remains the most common cause of mortality from malignant disease in the world for several decades, and it has been the most common cancer in China.[1] It is estimated that there are 1.8 million new cases in 2012, 58% of them occur in Correspondence: August 4, 2013 November 13, 2013 February 4, 2014 February 8, 2014 the less developed countries.[1] Non-small cell lung cancer (NSCLC) accounts for about 80% of lung cancer cases, and has a overall five-year survival rate of less than 15%.2,3. Detection of molecular markers could help design individualized chemotherapy to improve the survival of advanced NSCLC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
